华西医学

华西医学

双歧杆菌乳杆菌三联活菌片联合聚乙二醇 4000 散治疗老年慢性便秘的临床研究

查看全文

目的 观察双歧杆菌乳杆菌三联活菌片联合聚乙二醇 4000 散治疗老年人慢性便秘的临床疗效。 方法 将 2015 年 4 月—2016 年 4 月在老年医学中心门诊和住院的 120 例老年慢性便秘患者随机分配至 A 组(单用聚乙二醇 4000 散)和 B 组(双歧杆菌乳杆菌三联活菌片联合聚乙二醇 4000 散),观察两组患者治疗前后粪便性状(Bristol Stool Form Scale,BSFS)、便秘症状(Patient Assessment of Constipation Symptom,PAC-SYM)、日常生活活动功能(Constipation Related Disability,CRDS)等临床指标,评估临床疗效,记录药物的不良反应。 结果 A 组患者治疗前 BSFS、PAC-SYM、CRDS 分别为(1.98±0.77)、(37.87±4.12)、(31.03±3.19)分,治疗后分别为(3.87±0.82)、(28.55±2.15)、(18.56±1.80)分;B 组患者治疗前 BSFS、PAC-SYM、CRDS 分别为(2.03±0.78)、(36.25±4.98)、(30.28±3.56)分,治疗后分别为(4.80±0.75)、(19.73±3.42)、(13.80±2.36)分。两组患者治疗后各临床观察指标较治疗前均明显改善,差异有统计学意义(P<0.05);组间比较,B 组临床指标较 A 组改善更明显,差异有统计学意义(P<0.05)。未观察到严重不良反应。 结论 双歧杆菌乳杆菌三联活菌片联合聚乙二醇 4000 散对改善老年慢性便秘有理想效果。

Objective To explore the effect of triple viable bifidobacterium lactobacillus tablets combined with polyethylene glycol 4000 on elderly patients with chronic constipation. Methods This pilot study was conducted at the Center of Gerontology and Geriatrics, West China Hospital. A total of 120 patients with chronic constipation, aged 60 years or older, were enrolled from April 2015 to April 2016, and randomly assigned into group A (polyethylene glycol 4000) and group B (triple viable bifidobacterium lactobacillus tablets combined with polyethylene glycol 4000). All the patients were estimated before and after treatment, with Bristol Stool Form Scale (BSFS), Patient Assessment of Constipation Symptom (PAC-SYM) and Constipation Related Disability (CRDS), and adverse drug reactions were observed. Results In group A, before treatment, the scores of BSFS, PAC-SYM and CRDS were 1.98±0.77, 37.87±4.12 and 31.03±3.19, respectively; while after treatment, the scores of BSFS, PAC-SYM and CRDS were 3.87±0.82, 28.55±2.15 and 18.56±1.80, respectively, which were all significantly improved (P<0.05). In group B, before treatment, the scores of BSFS, PAC-SYM and CRDS were 2.03±0.78, 36.25±4.98 and 30.28±3.56, respectively; while after treatment, the score of BSFS, PAC-SYM and CRDS was 4.80±0.75, 19.73±3.42 and 13.80±2.36, respectively, which were all significantly improved (P<0.05). After treatment, compared with group A, the improvement of constipation in group B was significantly better (P<0.05). There was no adverse drug reaction observed. Conclusion Triple viable bifidobacterium lactobacillus tablets combined with polyethylene glycol 4000 may be an effective therapy for elderly patients with chronic constipation.

关键词: 双歧杆菌乳杆菌三联活菌片; 聚乙二醇 4000 散; 老年人; 慢性便秘

Key words: Triple viable bifidobacterium lactobacillus tablets; Polyethylene glycol 4000; Elderly; Chronic constipation

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. De Giorgio R, Ruggeri E, Stanghellini V, et al. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol, 2015, 15:130.
2. 余英. 老年性便秘与肠道菌群失调的相关性及药物干预性研究. 胃肠病学和肝病学杂志, 2010, 19(12): 1133-1135.
3. 翟力平, 王晓伟. 聚乙二醇 4000 治疗老年习惯性便秘疗效和安全性观察. 中国误诊学杂志, 2011, 11(3): 604.
4. 罗马委员会. 功能性胃肠病罗马Ⅲ诊断标准. 胃肠病学, 2006, 11(12): 761-765.
5. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol, 1997, 32(9): 920-924.
6. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol, 1999, 34(9): 870-877.
7. Hart SL, Albiani JJ, Crangle CJ, et al. Development and assessment of the constipation-related disability scale. Aliment Pharmacol Ther, 2012, 35(1): 183-192.
8. Lindberg G, Hamid SS, Malfertheiner PA, et al. World gastroenterology organisation global guideline Constipation. A global perspective. J Clin Gastroenterol, 2011, 45(6): 483-487.
9. 中华医学会消化病学分会胃肠动力学组. 中华医学会外科学分会结直肠肛门外科学组.中国慢性便秘诊治指南. 胃肠病学, 2013, 18(10): 605-611.
10. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science, 2012, 336(686): 1268-1273.
11. 何馥倩, 黄晓丽, 高凤娇, 等. 枯草杆菌二联活菌肠溶胶囊预防老年人抗生素相关性肠道菌群失调的临床研究. 华西医学, 2013, 28(1): 83-84.
12. Holma R, Hongisto SM, Saxelin M, et al. Constipation is relieved more by rye bread than wheat bread or laxatives without increased adverse gastrointestinal effects. J Nutr, 2010, 140(3): 534-541.
13. 刘海宁. 肠道菌群与功能性便秘的研究进展. 复旦学报: 医学版, 2015, 42(4): 564-568.
14. Zhao X, Suo HY, Qian Y, et al. Therapeutic effects of Lactobacillus casei Qian treatment in activated carbon-induced constipated mice. Mol Med Rep, 2015, 12(2): 3191-3199.
15. 周思远, 刘婷, 覃海知, 等. 临床常用便秘诊断和疗效评价量表的特征. 世界华人消化杂志, 2013, 21(25): 2611-2616.